Survodutide is a once-weekly dual glucagon and GLP-1 receptor agonist being investigated for obesity, metabolic disease, and metabolic dysfunction-associated steatohepatitis (MASH). Clinical trials have reported substantial body-weight reductions alongside metabolic and liver-related improvements.

Product Information

Survodutide activates both GLP-1 and glucagon receptors. Phase 2 research has evaluated it in adults with obesity and in people with MASH and liver fibrosis, with studies examining body weight, liver fat, fibrosis, glucose regulation, and other metabolic markers.

How It Works

GLP-1 receptor activation influences appetite and glucose regulation, while glucagon receptor activation affects energy metabolism and lipid handling. Survodutide combines these two signals into a single dual-action molecule.

Potential Benefits

1. Weight-Management Research

Phase 2 obesity research has demonstrated dose-dependent reductions in body weight with once-weekly survodutide. The strongest studied doses produced substantial average weight reductions over the treatment period.

2. Appetite Regulation

The GLP-1 component can reduce appetite and influence food intake, supporting the investigation of survodutide as a weight-management therapy.

3. Metabolic Support

Survodutide has been studied for effects on glucose-related and other metabolic biomarkers. Research has reported improvements in several measures related to metabolic function.

4. Liver Health Research

Survodutide has also been investigated in people with MASH and liver fibrosis. Phase 2 research has examined histological improvement, liver fat reduction, and changes in fibrosis.

Dosage

In a phase 2 obesity trial, survodutide was studied at once-weekly doses of 0.6, 2.4, 3.6, and 4.8 mg, using a dose-escalation and maintenance design over 46 weeks. These were research doses and should not be treated as individualized dosing instructions.

Side Effects

Gastrointestinal adverse effects are the most frequently reported issues in clinical research, including nausea, vomiting, diarrhea, constipation, and abdominal discomfort. In the phase 2 obesity trial, gastrointestinal events were more common with survodutide than placebo.

References

1. le Roux CW, Steen O, Lucas KJ, et al. Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial. Lancet Diabetes & Endocrinology. 2024;12(3):162-173. PMID: 38330987. PubMed
2. Sanyal AJ, Bedossa P, Fraessdorf M, et al. A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis. New England Journal of Medicine. 2024. PMID: 38847460. PubMed

BehemothLabz does not sell this product. Purchase links on this page may direct you to third-party suppliers through affiliate links.

Melanotan-1 is a synthetic analogue of alpha-melanocyte-stimulating hormone (α-MSH) that has been studied for its ability to stimulate melanin production. It is particularly associated with research into pigmentation and melanocortin signaling.

Product Information

Melanotan-1, also known as [Nle4-D-Phe7]-α-MSH, is a potent melanocortin peptide. Human research has demonstrated increased pigmentation following administration, while related melanocortin analogues have also been clinically investigated for pigmentation disorders.

How It Works

Melanotan-1 activates melanocortin receptors on melanocytes, stimulating the production of eumelanin. Increased eumelanin can result in darker skin pigmentation following exposure to the peptide.

Potential Benefits

1. Melanin Production

Melanotan-1 directly stimulates melanocortin pathways involved in melanin synthesis. Human studies have demonstrated measurable changes in pigmentation following administration.

2. Skin Pigmentation Research

Clinical research has shown that Melanotan-1 can produce measurable tanning effects after repeated administration. This makes it useful for studying melanocyte activity and pigmentation pathways.

3. Melanocortin Receptor Activity

The peptide provides a strong tool for investigating α-MSH-related signaling. Its effects help illustrate how melanocortin receptor activation can influence melanogenesis and pigmentation.

4. Photoprotective Research Interest

Because eumelanin absorbs and dissipates ultraviolet radiation, melanocortin signaling has been investigated for potential photoprotective applications. However, increased pigmentation should not be considered a substitute for established UV protection.

Dosage

Human research has used substantially different Melanotan-1 regimens depending on the study design. One pharmacokinetic study evaluated subcutaneous doses of approximately 0.08-0.21 mg/kg, with 0.16 mg/kg also studied by intravenous and oral routes. These historical research doses should not be interpreted as a recommended self-administration schedule.

Side Effects

Reported effects in the human study included occasional gastrointestinal upset and facial flushing. Changes in pigmentation, including increased skin darkening, were expected pharmacological effects. The long-term safety profile of non-approved Melanotan-1 use remains insufficiently established.

References

1. Ugwu SO, Blanchard J, Dorr RT, et al. Skin pigmentation and pharmacokinetics of melanotan-I in humans. Biopharmaceutics & Drug Disposition. 1997;18(3):259-269. PMID: 9113347. PubMed
2. Dorr RT, Ertl G, Levine N, et al. Increased eumelanin expression and tanning is induced by a superpotent melanotropin [Nle4-D-Phe7]-alpha-MSH in humans. Photochemistry and Photobiology. 2000. PMID: 11045725. PubMed

BehemothLabz does not sell this product. Purchase links on this page may direct you to third-party suppliers through affiliate links.

Mazdutide is a dual GLP-1 and glucagon receptor agonist developed to influence appetite, energy balance, glucose metabolism, and body weight. Clinical research has shown substantial weight reduction with once-weekly administration in adults with overweight or obesity.

Product Information

Mazdutide combines GLP-1 receptor activity with glucagon receptor activity. This dual mechanism is designed to pair GLP-1-mediated appetite and glucose effects with glucagon-mediated effects on energy expenditure and metabolism. A 2026 phase 2 trial evaluated once-weekly doses up to 16 mg in adults with obesity or overweight without type 2 diabetes.

How It Works

Mazdutide activates both GLP-1 and glucagon receptors. GLP-1 activity helps regulate appetite and glucose, while glucagon signaling influences energy expenditure and lipid metabolism, creating a dual pathway for metabolic and weight-management effects.

Potential Benefits

1. Body-Weight Reduction

Clinical trials have demonstrated meaningful reductions in body weight with once-weekly mazdutide. The magnitude of weight reduction has increased across studied dose ranges, making body-weight management one of its primary research areas.

2. Appetite Regulation

Through GLP-1 receptor activation, mazdutide can influence appetite and food intake. This mechanism may make it useful in research focused on sustained reductions in caloric intake and weight.

3. Metabolic Health

Mazdutide's dual-receptor activity is being investigated for broader metabolic effects beyond weight alone. Research has examined changes in glucose-related and cardiometabolic parameters alongside body-weight reduction.

4. Dual-Pathway Activity

Unlike a conventional GLP-1-only approach, mazdutide also activates glucagon receptors. This combination is designed to influence both appetite regulation and energy metabolism through complementary biological pathways.

Dosage

In a 2026 phase 2 obesity trial, once-weekly subcutaneous mazdutide was studied at 3-6 mg, 10 mg, and 16 mg over 48 weeks. These are clinical-trial doses, not a universal dosing recommendation; appropriate dosing depends on formulation, indication, titration, and clinical supervision.

Side Effects

Gastrointestinal effects such as nausea, vomiting, diarrhea, constipation, and abdominal discomfort are among the adverse effects commonly associated with GLP-1 and related incretin therapies. In the phase 2 trial, gastrointestinal adverse events were among the most common adverse effects reported.

References

1. Hsia SH, Bajaj M, Garvey WT, et al. Efficacy and safety of mazdutide in adults with obesity or overweight: a US-based, multicentre, phase 2, randomised, placebo-controlled clinical trial. Lancet Diabetes & Endocrinology. 2026. PMID: 42628555. PubMed

BehemothLabz does not sell this product. Purchase links on this page may direct you to third-party suppliers through affiliate links.

Cagrilintide is a long-acting amylin analogue developed to influence appetite, satiety, and energy intake. Clinical research has demonstrated meaningful body-weight reductions and has also investigated its use alongside GLP-1 receptor agonists.

Product Information

Cagrilintide acts through amylin-related pathways involved in satiety and food intake. In clinical research, once-weekly cagrilintide has produced dose-dependent reductions in body weight, while combination studies have examined complementary GLP-1 and amylin activity.

How It Works

Cagrilintide activates amylin-associated signaling that helps regulate appetite and food intake. Its long-acting design allows the pathway to be stimulated over an extended period following administration.

Potential Benefits

1. Appetite & Satiety Support

Amylin signaling contributes to feelings of fullness and regulation of food intake. Cagrilintide has been studied specifically for its ability to influence these pathways over an extended period.

2. Body-Weight Reduction

Phase 2 clinical research demonstrated dose-dependent weight reduction with once-weekly cagrilintide. This has made body-weight management one of its central areas of clinical investigation.

3. Complementary Metabolic Activity

Cagrilintide can be combined mechanistically with GLP-1 receptor agonism because the two pathways regulate appetite through different but complementary mechanisms.

4. Glycemic & Metabolic Research

Clinical studies of cagrilintide-containing regimens have evaluated changes in body weight, HbA1c, glucose measures, and other metabolic outcomes. This gives the peptide relevance beyond appetite alone.

Dosage

Clinical trials have studied once-weekly cagrilintide doses ranging from approximately 0.3 mg to 4.5 mg, generally with dose escalation. These are study protocols rather than individualized dosing instructions, and combination formulations can have substantially different dosing requirements.

Side Effects

The most commonly reported adverse effects include nausea, vomiting, diarrhea, constipation, abdominal discomfort, and decreased appetite. Gastrointestinal effects are particularly relevant during dose escalation.

References

1. Lau DCW, Erichsen L, Francisco AM, et al. Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. The Lancet. 2021;398(10317):2160-2172. PMID: 34798060. PubMed
2. Frias JP, Bajaj H, Dalskov SM, et al. Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2). Lancet Diabetes & Endocrinology. 2026. PMID: 42251859. PubMed

BehemothLabz does not sell this product. Purchase links on this page may direct you to third-party suppliers through affiliate links.

AHK-Cu is a copper-binding tripeptide studied primarily in hair-growth and skin-related research. It has attracted attention for its effects on dermal papilla cells, fibroblast activity, and biological processes involved in tissue maintenance.

Product Information

AHK-Cu is the copper complex of alanyl-histidyl-lysine. Experimental research has shown effects on cultured human dermal papilla cells and isolated human hair follicles, including increased follicle elongation and cell proliferation.

How It Works

AHK-Cu interacts with copper-dependent biological pathways and has been studied for its effects on dermal papilla cells and follicular tissue. Research suggests that it may support cellular activity involved in hair follicle growth.

Potential Benefits

1. Hair Follicle Research

AHK-Cu has demonstrated direct activity in ex vivo human hair follicles. Research found that the peptide promoted follicle elongation and supported proliferation of dermal papilla cells.

2. Dermal Papilla Support

Dermal papilla cells play a central role in hair follicle development and cycling. AHK-Cu has been studied for its ability to influence these cells, making it particularly relevant to hair-growth research.

3. Cellular Protection

Experimental findings suggest that AHK-Cu may influence apoptosis-related pathways in dermal papilla cells. These effects provide a mechanistic basis for continued investigation into its potential role in follicular biology.

4. Skin & Tissue Research

Copper peptides have broader research applications involving fibroblasts, tissue remodeling, collagen-related pathways, and wound biology. AHK-Cu belongs to this wider class of biologically active copper-peptide compounds.

Dosage

There is no established human therapeutic dose for AHK-Cu. Published laboratory research has investigated concentrations from approximately 10⁻¹² to 10⁻⁹ M in ex vivo human hair follicles and cultured dermal papilla cells. These experimental concentrations should not be converted directly into human dosing instructions.

Side Effects

Human safety data for isolated AHK-Cu are limited. With topical peptide products, possible concerns include local irritation, redness, sensitivity, or reactions to the overall formulation. Injectable or systemic use lacks an established clinical safety framework.

References

1. Pyo HK, Yoo HG, Won CH, et al. The effect of tripeptide-copper complex on human hair growth in vitro. Archives of Pharmacal Research. 2007;30(7):834-839. PMID: 17703734. PubMed
2. Maquart FX, Bellon G, Chaqour B, et al. Effect of tripeptide-copper complexes on the process of skin wound healing and on cultured fibroblasts. Archives Internationales de Pharmacodynamie et de Thérapie. 1995. PMID: 8836453. PubMed

BehemothLabz does not sell this product. Purchase links on this page may direct you to third-party suppliers through affiliate links.

Prostamax is a synthetic tetrapeptide composed of lysine, glutamic acid, aspartic acid, and proline (Lys-Glu-Asp-Pro). It belongs to the Khavinson short-peptide bioregulator family and is primarily associated with research involving prostate tissue, cellular differentiation, and age-related changes in prostatic function.

Product Information

Prostamax has been proposed as a tissue-specific peptide bioregulator targeting prostate-associated cellular processes. Research surrounding this peptide family has focused on tissue-specific gene expression and cellular differentiation, although direct evidence specifically establishing Prostamax's effects in humans remains limited.

The broader Khavinson peptide literature describes Prostamax as a prostate-associated tetrapeptide, but modern evidence reviews emphasize that direct human clinical evidence is sparse.

How It Works

The proposed mechanism of Prostamax involves short-peptide interactions with cellular regulatory systems, including chromatin and gene-expression processes. The tissue-specific bioregulator model proposes that these peptides may influence expression of genes associated with the target tissue, although the precise molecular mechanism remains incompletely established.

POTENTIAL BENEFITS

1. Prostate Research

Prostamax is primarily investigated in relation to prostate tissue and age-associated changes in prostatic function. This makes it relevant to research exploring peptide-based approaches to maintaining normal prostate-cell behavior.

2. Cellular Differentiation Research

The broader family of short tissue-specific peptides has demonstrated effects on differentiation-related gene expression in experimental models. Prostamax is therefore of interest in studies examining how peptide signals may influence tissue-specific cellular characteristics.

3. Prostate-Aging Research

Age-related changes in prostate tissue are an important area of biological research. Prostamax has been positioned within the peptide-bioregulator field as a compound for investigating how short peptides may influence aging-associated changes in prostate cells.

4. Gene-Expression Research

The proposed activity of Prostamax extends beyond conventional receptor signaling. Its research profile centers on potential effects on gene expression and chromatin regulation, providing a different model for investigating tissue-specific peptide signaling.

5. BPH-Related Research Interest

Prostamax is frequently discussed in connection with benign prostatic hyperplasia research. However, evidence directly demonstrating clinically meaningful effects in men with BPH remains insufficient, so this area should be regarded as a research interest rather than an established therapeutic benefit.

Dosage

There is no established human dosage for Prostamax.

Online peptide references may report amounts such as 20–40 mg/day, but these figures are not supported by robust clinical dose-finding studies and should be treated as reported market information rather than established medical dosing.

Side Effects

Human safety data are limited. Potential concerns include:

• Unknown long-term safety
• Individual sensitivity
• Possible gastrointestinal effects depending on administration
• Unknown interactions with medications

References

1. Khavinson VK, et al. Tissue-specific effects of peptides. PMID: 11713572. PubMed
2. Khavinson VK, et al. Mechanism of biological activity of short peptides. Research publication

Note: BehemothLabz does not sell this product. Purchase links on this page may direct you to third-party suppliers through affiliate links.

OS-01 is a synthetic peptide developed as a senotherapeutic and skin-aging research compound. It has attracted attention for its potential effects on cellular senescence, skin barrier function, texture, radiance, and visible signs of aging.

Product Information

OS-01, also known as Pep 14, has been investigated for its ability to influence biological processes associated with cellular aging. Unlike many experimental peptides that remain limited to laboratory models, OS-01 has also been evaluated in a small controlled human topical study.

A 12-week double-blind, vehicle-controlled study involving 22 women found that the OS-01 formulation produced greater improvements in several measured skin parameters than the vehicle formulation.

How It Works

OS-01 has been investigated as a senotherapeutic peptide intended to influence pathways associated with cellular aging and skin integrity. Research has focused on its relationship with senescent-cell biology, skin barrier function, and age-associated changes in skin structure.

POTENTIAL BENEFITS

1. Skin Barrier Support

Clinical research has reported improvements in skin barrier function following use of an OS-01-containing formulation. This makes the peptide particularly interesting for research into maintaining skin resilience as the skin ages.

2. Skin Texture Research

The 12-week controlled clinical study found improvements in measured skin texture with the OS-01 formulation. These findings support continued investigation of OS-01 as a peptide-based approach to age-associated skin changes.

3. Skin Radiance

OS-01 has also been investigated for its effect on skin radiance. The controlled study reported improvements in instrumental measures of radiance compared with the vehicle formulation, adding to the peptide's cosmetic research profile.

4. Wrinkle Research

The OS-01-containing formulation produced improvements in wrinkle indentation measurements compared with vehicle in the pilot clinical study. This makes it particularly relevant to research surrounding visible structural changes associated with skin aging.

5. Cellular-Aging Research

OS-01 is especially interesting because it is positioned around senescent-cell biology rather than simply providing a conventional moisturizing or cosmetic effect. Research continues to investigate whether modifying age-associated cellular processes can translate into broader improvements in tissue health.

Dosage

There is no established systemic human dosage for OS-01.

The available human evidence concerns topical application, including a 12-week controlled study of an OS-01-containing formulation. This evidence should not be extrapolated to injectable or systemic use.

Side Effects

The available topical clinical study reported the OS-01 formulation as well tolerated. Potential topical concerns may include:

• Temporary irritation
• Redness
• Dryness
• Individual sensitivity

Long-term systemic safety has not been established.

References

1. Zonari A, et al. Double-blind, vehicle-controlled clinical investigation of peptide OS-01 for skin rejuvenation. J Cosmet Dermatol. 2024. Clinical study
2. OS-01 Peptide Topical Formulation Improves Skin Barrier Function and Reduces Systemic Inflammation Markers. PMC

Note: BehemothLabz does not sell this product. Purchase links on this page may direct you to third-party suppliers through affiliate links.

Human Menopausal Gonadotropin (HMG), also known as menotropins, is a gonadotropin preparation containing follicle-stimulating hormone (FSH) and luteinizing hormone (LH) activity. It has an established role in reproductive medicine and has been extensively studied for controlled stimulation of ovarian follicular development and, in selected male patients, stimulation of spermatogenesis.

Product Information

HMG works through its FSH and LH activity to stimulate the reproductive system. In women, FSH promotes follicular development while LH contributes to steroidogenesis and ovulatory function. In men with hypogonadotropic hypogonadism, HMG can be used alongside hCG to stimulate testicular development and support spermatogenesis.

HMG is a clinically established gonadotropin rather than an experimental peptide, although its use requires appropriate medical monitoring because excessive stimulation can produce significant complications.

How It Works

The FSH component of HMG stimulates ovarian follicles or, in men, supports Sertoli-cell activity and sperm production. Its LH activity supports gonadal steroid production through stimulation of the relevant gonadal cells. The resulting hormonal effects depend heavily on the individual's underlying reproductive condition.

POTENTIAL BENEFITS

1. Follicular Development Research

HMG is widely studied for its ability to stimulate ovarian follicular development. Its FSH activity directly supports follicular growth, making it an important tool in controlled ovarian stimulation and assisted-reproduction research.

2. Supports Spermatogenesis Research

In men with hypogonadotropic hypogonadism, HMG has been investigated for stimulating testicular growth and initiating or supporting sperm production, particularly when hCG alone has not produced the desired response.

3. Reproductive Hormone Research

Because HMG combines FSH and LH activity, it provides researchers and clinicians with a way to study how gonadotropin signaling influences the ovaries and testes. This makes it particularly relevant to reproductive endocrinology.

4. Assisted-Reproduction Applications

HMG has a long history in fertility treatment and has been used to promote controlled ovarian stimulation before procedures such as assisted reproduction. Research has examined different dosing strategies and their effects on follicular recruitment and ovarian response.

5. Male Fertility Research

HMG has also been investigated in men with deficient pituitary gonadotropin signaling. Studies have reported stimulation of testicular growth and spermatogenesis when HMG is administered as part of appropriately monitored fertility treatment.

Dosage

HMG dosing is indication-specific and medically supervised rather than having one universal dose.

In historical male hypogonadotropic-hypogonadism research, regimens included 37.5 IU once or twice daily, while ovarian-stimulation studies have used substantially different regimens, including approximately 150 IU/day or higher, depending on treatment protocol and ovarian response.

Because excessive ovarian stimulation can cause ovarian hyperstimulation syndrome, dosing should be individualized and monitored clinically.

Side Effects

Potential side effects include:

• Injection-site reactions
• Headache
• Abdominal discomfort or bloating
• Ovarian enlargement
• Ovarian hyperstimulation syndrome
• Multiple pregnancy
• Gynecomastia or hormonal changes in men

References

1. Self-administered subcutaneous human menopausal gonadotrophin for stimulation of testicular growth and initiation of spermatogenesis in hypogonadotrophic hypogonadism. PMID: 8435901. PubMed
2. Ovulation induction with human menopausal gonadotrophins. PMID: 24600. PubMed
3. Increasing the human menopausal gonadotrophin dose. PMID: 2106451. PubMed

Note: BehemothLabz does not sell this product. Purchase links on this page may direct you to third-party suppliers through affiliate links.

Vasoactive Intestinal Peptide (VIP) is a neuropeptide made up of 28-amino-acids. It belongs to the secretin/glucagon peptide superfamily. It is endogenously made in neural, gastrointestinal, and immune-related tissues. VIP is being widely studied in experimental systems due to its diverse signaling roles. VIP interacts with specific G protein-coupled receptors. The primary among them are VPAC1 and VPAC2. Both are broadly expressed across various cell types in laboratory models. Its conserved structure and receptor affinity make it a valuable compound for checking intracellular signaling pathways and intercellular communication in controlled research environments.

Mechanism of Action

VIP shows its activity through binding to VPAC1 and VPAC2 receptors. These are members of the G protein-coupled receptor (GPCR) family. Upon receptor binding in experimental models, VIP activates intracellular G proteins. This leads to stimulation of adenylate cyclase. The results are increased levels of cyclic adenosine monophosphate (cAMP). It is a key secondary messenger involved in regulating cellular signaling cascades. The elevation of cAMP affects downstream pathways. This includes protein kinase A (PKA) activation and transcriptional modulation. All this has made researchers study signal transduction mechanisms and receptor-mediated cellular responses in laboratory settings.

Properties of VIP (Vasoactive Intestinal Peptide):

• Molecular Formula: C147H237N43O43S
  
• Molecular Weight: 3326.8 g/mol
  
• CAS Number: 122395-32-9
  
• PubChem CID: 16132380
  
• Synonyms: Vasoactive Intestinal Peptide, VIP, Vasoactive Intestinal Polypeptide, Intestinal Vasoactive Peptide
  
• Sequence Length: 28 amino acids
  
• IUPAC Name: H-His-Ser-Asp-Ala-Val-Phe-Thr-Asp-Asn-Tyr-Thr-Arg-Leu-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Asn-Ser-Ile-Leu-Asn-OH

Research Applications/Benefits of VIP (Vasoactive Intestinal Peptide)

Receptor Signaling Studies

VIP is widely used in laboratory research to investigate GPCR-mediated signaling. As stated earlier, it is particularly involved in VPAC1 and VPAC2 receptors. It serves as a model ligand for studying receptor activation, binding affinity, and downstream signaling pathways.

cAMP Pathway Analysis

Due to its ability to stimulate adenylate cyclase activity, VIP is frequently utilized in experimental systems. This is done in order to study cyclic AMP (cAMP)-dependent signaling mechanisms and their role in cellular communication.

Neurotransmission Research

VIP plays a key role in neuropeptide signaling. This makes it valuable in preclinical models examining neurotransmission, synaptic modulation, and neurochemical signaling networks.

Immunological Signaling Models

In controlled research environments, VIP is used to explore interactions between neuropeptides and immune-related cellular pathways. This helps in the understanding of signaling cross-talk in experimental systems.

Gastrointestinal System Research

VIP is applied in laboratory studies focusing on enteric signaling and peptide-mediated communication. It is mostly done within gastrointestinal models, providing insight into regulatory mechanisms at the cellular level.

Why Choose BehemothLabz to Buy VIP (Vasoactive Intestinal Peptide)

BehemothLabz is dedicated to providing high-quality research compounds manufactured under strict quality control standards. Each batch of VIP peptide is carefully synthesized and undergoes independent third-party testing to verify purity, composition, and consistency. With a strong emphasis on transparency and reliability, BehemothLabz supports researchers by delivering dependable materials suitable for advanced laboratory and experimental applications.

Disclaimer: This information is for educational purposes. We do not allow the human consumption of our products. All our products are sold for laboratory and research experiments.

ATTENTION: All BehemothLabz products are strictly for LABORATORY AND RESEARCH PURPOSES ONLY. They are not to be used for any human or veterinary purposes.

References:

1. Dickson L, Finlayson K. “VPAC and PAC receptors: From ligands to function.” Pharmacology & Therapeutics. 2009;121(3):294–316. https://doi.org/10.1016/j.pharmthera.2008.11.006
2. Gozes I, Brenneman DE. “VIP: Molecular biology and neurobiological function.” Molecular Neurobiology. 1989;3(4):201–236. https://doi.org/10.1007/BF02935683

Vilon is a synthetic peptide commonly studied in preclinical models for its regulatory effects on cellular and metabolic pathways. It is produced in a laboratory environment and supplied as a lyophilized powder for experimental use. Researchers utilize Vilon to investigate its potential role in signaling modulation, stress response regulation, and tissue-level biochemical activity in controlled experimental systems.

In laboratory settings, Vilon has been explored for its capacity to influence protein expression, gene regulation, and cellular signaling pathways. Early studies suggest that Vilon may play a role in modulating stress-related biochemical markers in preclinical models.

Mechanism of Action

In preclinical studies, Vilon is administered to research models under controlled experimental conditions. Upon reconstitution, the peptide is expected to interact with specific receptor pathways, leading to modulation of downstream signaling events.

These interactions may influence cellular responses, gene transcription patterns, and enzymatic activities observed in preclinical systems. Through this mechanism, Vilon is hypothesized to regulate stress-response pathways, maintain homeostatic balance, and modulate biochemical activity within experimental tissues.

Properties of Vilon: 

• Molecular Formula: C11H21N3O5

• Molecular Weight: 275.30 g/mol

• CAS Number: 45234-02-4

• PubChem CID: 7010502

• Synonyms: lysylglutamic acid, 45234-02-4, Lys-Glu, Peptide vilon

Research Applications/Benefits of Vilon

Modulation of Cellular Stress Responses:

Vilon is studied for its potential to influence cellular signaling pathways associated with stress markers. Early experiments indicate that it may regulate expression patterns in stress-related proteins during controlled experiments.

Regulation of Biochemical Activity:

Researchers investigate Vilon to understand its capacity to affect enzymatic and metabolic activity in preclinical models. Observations suggest it may contribute to maintaining biochemical equilibrium in experimental conditions.

Influence on Gene Expression Pathways:

Vilon has been used in studies exploring transcriptional regulation in preclinical systems. Initial findings propose that it may modulate the activation of certain genes, offering a tool for studying gene-pathway interactions in research models.

Experimental Oxidative Balance Modulation:

Some preclinical experiments investigate Vilon for its potential role in balancing oxidative markers within controlled systems. This may provide insights into oxidative regulation mechanisms in experimental studies.

Why Choose BehemothLabz to Buy Vilon

At Behemoth Labz, precision and reliability are at the core of every product we supply. Our Vilon peptide is manufactured to meet rigorous laboratory-grade standards, ensuring consistency and integrity for all experimental applications.

Each batch is independently verified for purity and composition, providing researchers with confidence that their studies are supported by high-quality materials.

We also prioritize secure, confidential delivery for both national and international shipments, with payment processing designed to safeguard your information at every step.

Disclaimer: This information is for educational purposes. We do not allow the human consumption of our products. All our products are sold for laboratory and research experiments. 

References: 

1. Lezhava, T., Khavison, V., Monaselidze, J., Jokhadze, T., Dvalishvili, N., Bablishvili, N., & Barbakadze, S. (2004). Bioregulator Vilon-Induced Reactivation of Chromatin in Cultured Lymphocytes from Old People. Biogerontology, 5(2), 73–79. https://doi.org/10.1023/b:bgen.0000025070.90330.7f
2. Avolio, F., Martinotti, S., Khavinson, V. K., Esposito, J. E., Giambuzzi, G., Marino, A., Mironova, E., Pulcini, R., Robuffo, I., Bologna, G., Simeone, P., Lanuti, P., Guarnieri, S., Trofimova, S., Procopio, A. D., & Toniato, E. (2022). Peptides regulating proliferative activity and inflammatory pathways in the Monocyte/Macrophage THP-1 cell line. International Journal of Molecular Sciences, 23(7), 3607. https://doi.org/10.3390/ijms23073607
3. Sevostianova, N. N., Linkova, N. S., Polyakova, V. O., Chervyakova, N. A., Kostylev, A. V., Durnova, A. O., Kvetnoy, I. M., Abdulragimov, R. I., & Khavinson, V. H. (2013). Immunomodulating effects of vilon and its analogue in the culture of human and animal thymus cells. Bulletin of Experimental Biology and Medicine, 154(4), 562–565. https://doi.org/10.1007/s10517-013-2000-0